Literature DB >> 27079185

Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer.

Zofia Piotrowska1, Benjamin Drapkin2, Jeffrey A Engelman3, Rebecca J Nagy4, Richard B Lanman4, Lecia V Sequist3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27079185     DOI： 10.1016/j.jtho.2016.03.020

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  8 in total

1.  Rebuttal from Dr. Mino-Kenudson.

Authors:  Mari Mino-Kenudson
Journal:  Transl Lung Cancer Res       Date:  2016-08

2.  Cons: Can liquid biopsy replace tissue biopsy?-the US experience.

Authors:  Mari Mino-Kenudson
Journal:  Transl Lung Cancer Res       Date:  2016-08

3.  Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.

Authors:  Caroline E McCoach; Collin M Blakely; Kimberly C Banks; Benjamin Levy; Ben M Chue; Victoria M Raymond; Anh T Le; Christine E Lee; Joseph Diaz; Saiama N Waqar; William T Purcell; Dara L Aisner; Kurtis D Davies; Richard B Lanman; Alice T Shaw; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2018-03-29       Impact factor: 12.531

Review 4.  Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Bin-Chi Liao; Chia-Chi Lin; Jih-Hsiang Lee; James Chih-Hsin Yang
Journal:  J Biomed Sci       Date:  2016-12-03       Impact factor: 8.410

5.  Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.

Authors:  Victoria Villaflor; Brian Won; Rebecca Nagy; Kimberly Banks; Richard B Lanman; AmirAli Talasaz; Ravi Salgia
Journal:  Oncotarget       Date:  2016-10-11

6.  Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatment.

Authors:  Po-Lan Su; Szu-Chun Yang; Yi-Lin Chen; Yi-Lin Wu; Chia-Ying Lin; Wei-Yuan Chang; Yau-Lin Tseng; Wu-Wei Lai; Chung-Liang Ho; Chien-Chung Lin; Wu-Chou Su
Journal:  Cancer Med       Date:  2019-08-21       Impact factor: 4.452

7.  Clinical utility of circulating cell-free DNA in advanced colorectal cancer.

Authors:  Allan A Lima Pereira; Maria Pia Morelli; Michael Overman; Bryan Kee; David Fogelman; Eduardo Vilar; Imad Shureiqi; Kanwal Raghav; Cathy Eng; Shanequa Manuel; Shadarra Crosby; Robert A Wolff; Kimberly Banks; Richard Lanman; AmirAli Talasaz; Scott Kopetz; Van Morris
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240

8.  Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden.

Authors:  Manuel Caitano Maia; Paulo Gustavo Bergerot; Nazli Dizman; JoAnn Hsu; Jeremy Jones; Richard B Lanman; Kimberly C Banks; Sumanta K Pal
Journal:  Kidney Cancer       Date:  2017-07-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.